Article
Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.
Leukemia research - 1 May 2018
Choi Eun-Ji, Lee Je-Hwan, Lee Jung-Hee, Park Han-Seung, Ko Sun-Hye, Hur Eun-Hye, Moon Juhyun, Goo Bon-Kwan, Kim Yeonhee, Seol Miee, Lee Young-Shin, Kang Young-Ah, Jeon Mijin, Woo Ji Min, Lee Kyoo-Hyung
Abstract excerpt
This retrospective analysis compared anthracyclines (as part of an induction regimen) in 128 newly diagnosed FLT3-ITD-mutated AML patients. Induction regimens comprised high-dose daunorubicin (HD-DN; 90 mg/m2/d × 3d; n = 44), standard-dose daunorubicin (SD-DN; 45 mg/m2/d × 3d; n = 51), or idarubicin (IDA; 12 mg/m2/d × 3d; n = 33) in combination with cytarabine (100-200 mg/m2/d × 7d). Fifty-three patients showing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.